Share “News Summary: Elan, Biogen revise Tysabri...”

News Summary: Elan, Biogen revise Tysabri deal

Published on NewsOK Modified: February 6, 2013 at 5:08 pm •  Published: February 6, 2013
Advertisement

TAKING OVER: Biogen Idec will take over full ownership of the multiple sclerosis treatment Tysabri from its partner Elan Corp. PLC in exchange for a $3.25 billion cash payment and royalties on future sales.

CAPITAL IDEA: The drug developers currently split earnings from Tysabri, but Elan said the new deal will give it capital for investing and growing its business.

DIRECT INJECT: Tysabri is a drug taken intravenously once a month to combat to treat a form of multiple sclerosis that cycles between stages of relapse and remission.


AROUND THE WEB

  1. 1
    OKC Thunder's Russell Westbrook Marries Nina Earl in Star-Studded Beverly Hills Ceremony
  2. 2
    Obama Renames Mt. McKinley 'Denali' Ahead of Alaska Trip
  3. 3
    2015 US Open -- Maria Sharapova announces she will not play
  4. 4
    Neurologist and Writer Oliver Sacks Dies at 82
  5. 5
    What "Games Of Thrones" Characters Look Like In The Books
+ show more

FEATURED JOBS



× Trending business Article